Preclinical oncology

Kähkönen TE, Halleen JM, Bernoulli J 2022 Preclinical Osteoimmuno-Oncology Models to Study Effects of Immunotherapies on Bone Metastasis. Chapter in the book Animal Models for the Development of Cancer Immunotherapy, pages 167-209. John Wiley & Sons, Inc.

Kähkönen TE, Toriseva M, Petruk N, Virta A-R, Maher A, Eigéliené N, Kaivola J, Boström P, Koskivuo I , Nees M, Tuomela JM, Ivaska KK, Härkönen PL 2020 Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures. Cell Oncol (Dordr). doi: 10.1007/s13402-020-00562-0.

Valta M, Ylä-Pelto J, Lan Y, Kähkönen T, Taimen P, Boström PJ, Ettala O, Khan S, Paulin N, Elo LL, Koskinen PJ, Härkönen P, Tuomela J 2020 Critical evaluation of the subcutaneous engraftments of hormone naïve primary prostate cancer. Transl Androl Urol 9(3):1120–1134.

Kähkönen TE, Halleen JM, Bernoulli J 2020 Immunotherapies and metastatic cancers: understanding utility and predictivity of human immune cell engrafted mice in preclinical drug development. Cancers 12(6):1615 (invited review article).

Kähkönen TE, Halleen JM, Bernoulli J 2019 Potential of Targeting Bone Metastases with Immunotherapies. Nov Appro In Can Study 3(3):269-270 (invited review article).

Kähkönen TE, Suominen MI, Mäki-Jouppila JHE, Halleen JM, Tanaka A, Seiler M, Bernoulli J 2019 Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone. J Immunol Res 2019/4260987.

Kähkönen TE, Bernoulli J, Halleen JM, Suominen MI 2019 Novel and Conventional Preclinical Models to Investigate Bone Metastasis. Curr Mol Biol Rep 5(1):48-54 (invited review article).

Kähkönen TE, Tuomela JM, Grönroos TJ, Halleen JM, Ivaska KK, Härkönen PL 2018 Dovitinib dilactic acid reduces tumor growth and tumor-induced bone changes in an experimental breast cancer bone growth model. J Bone Oncol 16:100232.

Juzeniene A, Bernoulli J, Suominen M, Halleen J, Larsen RH 2018 Antitumor Activity of Novel Bone-seeking, α-emitting 224Ra-solution in a Breast Cancer Skeletal Metastases Model. Anticancer Res 38(4):1947-1955.

Suominen MI, Fagerlund KM, Rissanen JP, Konkol Y, Morko J, Peng Z, Alhoniemi E, Laine S, Corey E, Mumberg D, Ziegelbauer K, Käkönen S, Halleen JM, Vessella  R, Scholz A 2017 Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res 23(15):4335-46.

Valta M, Fagerlund K, Suominen M, Halleen J, Tuomela J 2015 Importance of microenvironment in preclinical models of breast and prostate cancer. World J Pharmacol 4:47-57 (invited review article).

Suominen MI, Rissanen JP, Käkönen R, Fagerlund KM, Alhoniemi E, Mumberg D, Ziegelbauer K, Halleen JM, Käkönen SM, Scholz A 2013 Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J Natl Cancer Inst 105:908-916.

Pollari S, Käkönen RS, Mohammad KS, Rissanen JP, Halleen JM, Wärri A, Nissinen L, Pihlavisto M, Marjamäki A, Perälä M, Guise TA, Kallioniemi O, Käkönen SM 2012 Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. Mol Cancer Res 10:597-604.